Liraglutide
Established medicinePrimarily used for Obesity & Type 2 Diabetes Mellitus.
Also known as Saxenda, Victoza, Xultophy, Liraglutida+2 more
Saxenda, Victoza, Xultophy, Liraglutida, Liraglutide recombinant, Liraglutidum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Approval: Liraglutide STADA (EMA)
Approval: LIRAGLUTIDE (ANDA212972)
Approval: LIRAGLUTIDE (ANDA213155)
Saxenda: Underlying Mechanisms and Clinical Outcomes
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges.
Evidence confidence
How strongly the incorporated evidence supports specific clinical claims about this treatment. A confidence figure is a current summary of evidence strength, not a permanent verdict.
— 37 supporting evidence families · 2 well-powered no-effect results · contradictory evidence
Confidence is moderated by well-powered no-effect evidence, despite broad trial support.
- 63%
- 39%
Evidence in deficiency-selected reaches a different conclusion (weak) from the general population (supported).
- 63%
- 15%
Evidence in PCOS reaches a different conclusion (against) from the general population (supported).
— 47 supporting evidence families · 7 well-powered no-effect results
Confidence is moderated by well-powered no-effect evidence and limited publication incorporation, despite broad trial support.
- 67%
- 29%
Evidence in deficiency-selected reaches a different conclusion (weak) from the general population (supported).
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of weight management.
Evidence ↗Indication: Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise
Evidence ↗Indication: Treatment of weight management.
Evidence ↗Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- Diabetes care26
- Diabetes, obesity & metabolism18
- The New England journal of medicine6
- International journal of obesity (2005)4
- Lancet (London, England)4
- Circulation3
- Buse JB19
- Nauck MA14
- Younes N13
- Krause-Steinrauf H12
- Marso SP12
- Zinman B10
- Jensen CB8
- Bergenstal RM7
- The Biostatistics Center13
- University of Michigan10
- University of North Carolina School of Medicine10
- Pennington Biomedical Research Center7
- University of Alabama at Birmingham6
- University of Copenhagen6
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Acts on the same molecular target as Liraglutide, with 20 overlapping disease areas.
Acts on the same molecular target as Liraglutide, with 11 overlapping disease areas.
Acts on the same molecular target as Liraglutide, with 11 overlapping disease areas.
Acts on the same molecular target as Liraglutide, with 9 overlapping disease areas.
Studied across 21 of the same disease areas as Liraglutide in the shared literature.
Studied across 11 of the same disease areas as Liraglutide in the shared literature.
Studied across 11 of the same disease areas as Liraglutide in the shared literature.
Studied across 11 of the same disease areas as Liraglutide in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.